<DOC>
	<DOCNO>NCT00004217</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PSC 833 may help chemotherapy drug kill cancer cell make sensitive drug . PURPOSE : Phase II trial study effectiveness PSC 833 , daunorubicin , cytarabine treat old patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>S9918 PSC 833 , Daunorubicin , Cytarabine Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy daunorubicin cytarabine continuous infusion PSC 833 patient age 56 newly diagnose acute myeloid leukemia . II . Determine frequency severity toxicity regimen patient . III . Determine frequency prognosis functional phenotypic P-glycoprotein expression , cytogenetics , pharmacokinetics population . OUTLINE : This multicenter study . Patients receive induction chemotherapy consist PSC 833 IV 2 hour day 1 , continuously 96 hour ; daunorubicin IV continuously day 1-3 ; cytarabine IV continuously day 1-7 . Filgrastim ( G-CSF ) sargramostim ( GM-CSF ) administer subcutaneously ( SQ ) IV begin day 15 continue blood count recover day 21 . If patient achieve complete remission one course , second course administer . Patients achieve A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status 1 2 course induction chemotherapy proceed consolidation therapy , begin upon recovery induction therapy . Consolidation therapy consist PSC 833 2 hour day 1 , daunorubicin IV 1-5 minute day 1 2 , cytarabine IV continuously day 1-5 . Treatment repeat total 2 course . Patients follow every 6 month 2 year annually 3 year . PROJECTED ACCRUAL : A total 20-55 patient accrue study within 8-9 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia ( AML ) No M3 AML blastic phase chronic myelogenous leukemia Must register protocol SWOG9007 SWOG9910 PATIENT CHARACTERISTICS : Age : 56 Performance status : Zubrod 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT/SGPT great 4 time ULN Renal : Creatinine great 1.5 time ULN Creatinine clearance great 40 mL/min Cardiovascular : LVEF least 50 % MUGA echocardiogram No unstable cardiac arrhythmia angina Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except : Adequately treat basal cell squamous cell skin cancer Carcinoma situ cervix Adequately treat stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy acute leukemia Prior hydroxyurea control high cell count allow At least 30 day since prior low dose cytarabine ( le 100 mg/m2/day ) myelodysplastic syndrome recover Single dose prior concurrent ( induction chemotherapy ) intrathecal chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>